Skip to main content
SpringerLink
Log in

Pharmacology of GRF and Somatostatin: Positive and Negative Control of GH Release

  • Conference paper
Growth Hormone II

Part of the book series: Serono Symposia USA Norwell, Massachusetts ((SERONOSYMP))

Abstract

The physiological mechanism(s) controlling the release of growth hormone (GH) from the adenohypophysis is unique in having two hormones, growth hormone releasing factor (GRF) (1, 2) and somatostatin (SRIF) (3), that cause either the release or inhibition of release of GH, respectively. In addition to these two primary control substances, however, many other events also impinge on the process, some of which are summarized in Figure 1.1. These events include negative feedback loops involving GRF, SRIF, GH, and IGF, as well as the involvement of additional peptide factors such as bombesin/gastrin releasing peptide, galanin, and the opiate peptides (in which group can be classified the synthetic growth hormone releasing peptides [GHRPs], which are also discussed in another chapter). Additionally, it is recently apparent that SRIF analogs can act at the hypothalamic level to inhibit the release of GRF directly (4).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Guillemin R, Brazeau P, Bohlem P, Esch F, Ling N, Wehrenberg F. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 1982;218:585–7.

    Article  PubMed  CAS  Google Scholar 

  2. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973;179:77–9.

    Article  PubMed  CAS  Google Scholar 

  3. Rivier JE, Spiess J, Thorner JM, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumor. Nature 1982;300:276–8.

    Article  PubMed  CAS  Google Scholar 

  4. Magnan E, Cataldi C, Guillaume V, et al. Acute changes in growth hormone-releasing hormone secretion after injection of BIM 23014, a long-acting somatostatin analog, in rams. Life Sci 1992;51:831–8.

    Article  PubMed  CAS  Google Scholar 

  5. Meyers CA, Coy DH. Somatostatin, enkephalins, and endorphins. In: Glass GBJ, ed. Gastrointestinal hormones. New York: Raven Press, 1980:363–85.

    Google Scholar 

  6. Konturek SJ. Somatostatin and opiate peptides: their action on gastrointestinal secretions. In: Glass GBJ, ed. Gastrointestinal hormones. New York: Raven Press, 1980:693–716.

    Google Scholar 

  7. Reichlin S. Somatostatin. N Engl J Med 1983;309:1495–556.

    Article  PubMed  CAS  Google Scholar 

  8. Moreau J-P, Defeudis FV. Pharmacological studies of somatostatin and somatostatin analogues: therapeutic advances and perspectives. Life Sci 1987;40:419–37.

    Article  PubMed  CAS  Google Scholar 

  9. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S. Cloning and functional expression of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract and kidney. Proc Natl Acad Sci USA 1992;89:251–5.

    Article  PubMed  CAS  Google Scholar 

  10. Yasuda K, Rens-Domiano S, Breder CD, et al. Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylcyclase. J Biol Chem 1992;267.

    Google Scholar 

  11. Rivier J, Brown M, Rivier C, Ling N, Vale W. In: Loffet A, ed. Peptides, 1976. Brussels: Universite de Bruxelles, 1976:427.

    Google Scholar 

  12. Vale W, Rivier J, Ling N, Brown M. Biological and immunologic activities and applications of somatostatin analogs. Metabolism 1978;27(suppl 1): 1391–401.

    Article  PubMed  CAS  Google Scholar 

  13. Holladay LA, Puett D. Conformational studies on somatostatin and analogues. Somatostatin conformation: evidence for a stable intramolecular structure from circular dichroism, diffusion, and sedimentation equilibrium. Proc Natl Acad Sci USA 1976;73:1199–202.

    Article  PubMed  CAS  Google Scholar 

  14. Holladay L, Rivier J, Puett D. Conformational studies on somatostatin and analogues. Biochemistry 1977;16:4895–900.

    Article  PubMed  CAS  Google Scholar 

  15. Rivier J, Brown M, Vale W. D-Trp8-somatostatin: an analog of somatostatin more potent than the native molecule. Biochem Biophys Res Commun 1975;65:746–51.

    Article  PubMed  CAS  Google Scholar 

  16. Veber DF, Holly FW, Palaveda WJ, et al. Conformationally restricted bicyclic analogs of somatostatin. Proc Natl Acad Sci USA 1978;75:2636–40.

    Article  PubMed  CAS  Google Scholar 

  17. Arison BH, Hirschmann R, Veber DF. Inferences about the conformation of somatostatin at a biologic receptor based on NMR studies. Bioorg Chem 1978;7:447–51.

    Article  CAS  Google Scholar 

  18. Veber DF, Holly FW, Nutt RF, et al. Highly active cyclic and bicyclic somatostatin analogues of reduced ring size. Nature 1979;280:512–4.

    Article  PubMed  CAS  Google Scholar 

  19. Veber DF, Friedinger RM, Perlow DS, et al. A potent cyclic hexapeptide analogue of somatostatin. Nature 1981;292:55–8.

    Article  PubMed  CAS  Google Scholar 

  20. Freidinger RM, Perlow DS, Randall WC, Saperstein R, Arison BH, Veber DF. Conformational modifications of cyclic hexapeptide somatostatin analogs. Int J Pept Protein Res 1984;23:142–50.

    Article  PubMed  CAS  Google Scholar 

  21. Veber DF, Saperstein R, Nutt RF, et al. A superactive cyclic hexapeptide analog of somatostatin. Life Sci 1984;34:1371–8.

    Article  PubMed  CAS  Google Scholar 

  22. Bauer W, Briner U, Doepfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:1133–40.

    Article  PubMed  CAS  Google Scholar 

  23. Heiman ML, Murphy WA, Coy DH. Differential binding of somatostatin agonists to somatostatin receptors in brain and adenohypophysis. Neuro-endocrinology 1987;45:429–36.

    CAS  Google Scholar 

  24. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991;12: 450–82.

    Article  PubMed  CAS  Google Scholar 

  25. Murphy WA, Taylor JE, Moreau JP, Coy DH. Novel heptapeptide somatostatin analog displays anti-tumor activity independent of effects on growth hormone secretion. Pept Res 1989;2:128–32.

    PubMed  CAS  Google Scholar 

  26. Bogden AE, Taylor JE, Moreau JP, Coy DH. Treatment of R-3327 prostate tumors with a somatostatin analogue (somatuline) as adjuvant therapy following surgical castration. Cancer Res 1990;50:2646–50.

    PubMed  CAS  Google Scholar 

  27. Taylor JE, Coy DH, Moreau JP. High affinity binding of [125I-Tyr11]-somatostatin-14 to human small cell lung carcinoma (NCI-H69). Life Sci 1988;43:421–8.

    Article  PubMed  CAS  Google Scholar 

  28. Taylor JE, Bogden AE, Moreau JP, Coy DH. In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue. Biochem Biophys Res Commun 1988;163:81–6.

    Article  Google Scholar 

  29. Murphy WA, Lance VA, Moreau S, Moreau JP, Coy DH. Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin. Life Sci 1987;40:2515–22.

    Article  PubMed  CAS  Google Scholar 

  30. Murphy WA, Taylor JE, Moreau JP, Coy DH. Linear octapeptide analogs of somatostatin retaining biological activity and ability to displace 125I-Tyr11-SRIF binding [Abstract]. 71st Endocr Soc meet, 1990:104.

    Google Scholar 

  31. Verheyden PMF, Coy DH, Van Binst G. Conformational study of somatostatin analogues in methanol at low temperature. Magn Reson Chem 1991; 29:607–12.

    Article  CAS  Google Scholar 

  32. Maurer R, Gaehwiler BH, Buescher HH, Hill RC, Roemer D. Opiate antagonist properties of an octapeptide somatostatin analog. Proc Natl Acad Sci USA 1982;79:4815–7.

    Article  PubMed  CAS  Google Scholar 

  33. Walker JM, Bowen WD, Akins ST, Hemstreet MK, Coy DH. μ-Opiate binding and morphine antagonism by octapeptide analogs of somatostatin. Peptides 1987;8:869–75.

    Article  PubMed  CAS  Google Scholar 

  34. Jensen RT, Coy DH. Progress in the development of potent bombesin receptor antagonists. Trends Pharmacol Sci 1991;12:13–9.

    Article  PubMed  CAS  Google Scholar 

  35. Fries JL, Murphy WA, Sueiraz-Diaz J, Coy DH. Somatostatin antagonist analog increases GH, insulin, and glucagon release in the rat. Peptides 1982;3:811–4.

    Article  PubMed  CAS  Google Scholar 

  36. Coy DH, Murphy WA, Fries JL, Sueiras-Diaz J. Potent, short cyclic peptide antagonists of somatostatin. Regul Pept 1983;suppl 2:S101.

    Google Scholar 

  37. Coy DH, Murphy WA, Lance VA, Hocart SJ, Sueiras-Diaz J, Mezo I. Somatostatin agonists and antagonists—peptide control of growth hormone secretion. In: Patel YC, Tannenbaum GS, eds. Somatostatin. Advances in experimental medicine and biology. New York: Plenum, 1985;188:325–37.

    Google Scholar 

  38. Raynor K, Coy DH, Reisine T. Analogues of somatostatin bind selectively to brain somatostatin receptor subtypes. J Neurochem 1992;59:1241–50.

    Article  PubMed  CAS  Google Scholar 

  39. Spiess J, Rivier J, Vale W. Characterization of rat hypothalamic growth hormone-releasing factor. Nature 1983;303:532–5.

    Article  PubMed  CAS  Google Scholar 

  40. Wehrenberg WB, Ling N, Brazeau P, et al. Somatocrinin, growth hormone-releasing factor, stimulates secretion of growth hormone in anesthetized rats. Biochem Biophys Res Commun 1982;109:382–6.

    Article  PubMed  CAS  Google Scholar 

  41. Rosenthal SM, Schriock EA, Kaplan SL, Guilleman R, Grumbach MM. Effect of growth hormone (GH)-releasing hormone (GRH) on plasma GH in relation to magnitude and duration of GH deficiency in 26 children and adults with isolated GH deficiency or multiple pituitary hormone deficiencies: evidence for hypothalamic GRH deficiency. J Clin Endocrinol Metab 1983;57:677–9.

    Article  PubMed  CAS  Google Scholar 

  42. Thorner MO, Rivier J, Spiess J, et al. Human pancreatic growth hormone releasing factor selectively stimulates growth hormone secretion in man. Lancet 1983;i:24–8.

    Google Scholar 

  43. Lance VA, Murphy WA, Sueiras-Diaz J, Coy DH. Super-active analogs of growth hormone-releasing factor (1–29)-amide. Biochem Biophys Res Commun 1984;119:265–72.

    Article  PubMed  CAS  Google Scholar 

  44. Murphy WA, Coy DH, Lance VA. Superactive amidated COOH-terminal glucagon analogs with no methionine or tryptophan. Peptides 1986;7(suppl l):69–74.

    Article  PubMed  CAS  Google Scholar 

  45. Felix AM, Heimer EP, Mowies TF, et al. Synthesis and biological activity of novel GRF analogs. In: Theodoropoulos D, ed. Proc 19th European Peptide Symposium. Berlin: de Gruyter, 1987:481–4.

    Google Scholar 

  46. Coy DH, Hocart SJ, Murphy WA. Human growth hormone-releasing hormone analogues with much improved in vitro growth hormone-releasing potencies in rat pituitary cells. Eur J Pharmacol 1991;204:179–85.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. David H. Coy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William A. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Simon J. Hocart
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pediatric Endocrinology, All Children’s Hospital, St. Petersburg, FL, 33701, USA

    Barry B. Bercu M.D.  & Richard F. Walker Ph.D.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag New York, Inc.

About this paper

Cite this paper

Coy, D.H., Murphy, W.A., Hocart, S.J., Taylor, J. (1994). Pharmacology of GRF and Somatostatin: Positive and Negative Control of GH Release. In: Bercu, B.B., Walker, R.F. (eds) Growth Hormone II. Serono Symposia USA Norwell, Massachusetts. Springer, New York, NY. https://doi.org/10.1007/978-1-4613-8372-7_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-8372-7_1

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4613-8374-1

  • Online ISBN: 978-1-4613-8372-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation